Azathioprine

Evidence Level: L5

Predicted Indications: 7

Azathioprine

Pharmacist Assessment Report

Azathioprine: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome

One-Sentence Summary

Azathioprine is an immunosuppressant (a purine antimetabolite) originally used for rheumatoid arthritis. The TxGNN model predicts it may be effective for colobomatous microphthalmia-rhizomelic dysplasia syndrome, a rare developmental malformation syndrome, but there are 0 clinical trials and 0 publications supporting this prediction, so it rests on model output alone.

Quick Overview

Item	Content
Original Indication	Rheumatoid arthritis
Predicted New Indication	Colobomatous microphthalmia-rhizomelic dysplasia syndrome
TxGNN Prediction Score	1.0000
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, azathioprine is a thiopurine immunosuppressant, and its efficacy in rheumatoid arthritis and other immune-mediated conditions is established.

For this specific prediction, however, no plausible mechanistic link could be identified. The predicted condition is a rare developmental malformation syndrome. Azathioprine’s immunosuppressive, purine-antimetabolite action has no known relevance to its underlying biology. The very high score from the TxGNN model (deep learning) (1.0000) may reflect similarities the model learned between related diseases, not biological evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Azathioprine is marketed in India as single-ingredient oral tablets, with 20 valid registrations and none cancelled. The registrations listed in the compiled data carry no approved-indication text. Five of them are shown below.

Authorization Number	Product Name	Dosage Form	Manufacturer
11651	Azatoz 50mg Tablet	Strip of 10 tablets	Cytoz Pharmaceuticals
7004	Azawan Tablet	Strip of 10 tablets	Rowan Bioceuticals Pvt Ltd
3093	Aprin 50mg Tablet	Strip of 10 tablets	Aegis Pharmaceuticals
11695	Azoalfa 50 Tablet	Strip of 10 tablets	Alniche Life Sciences Pvt Ltd
234855	Vaprin Tablet	Strip of 10 tablets	Zydus Cadila

Safety Considerations

Conditions flagged as contraindication-related in the knowledge graph (not drawn from label text): pancreatitis, thrombocytopenia, anaemia (including macrocytic anaemia), impaired renal function, infectious disease (including fungal infection and dermatophytosis), lymphoma (including primary CNS lymphoma, lymphosarcoma and hepatosplenic T-cell lymphoma), hepatic vein thrombosis and Budd-Chiari syndrome.
Drug Interactions: 447 interactions were recorded. The main moderate-level ones are the aminosalicylates mesalazine, balsalazide, olsalazine and sulfasalazine. Minor interactions include zinc salts (acetate, gluconate, sulfate).
Considerations for the predicted indication: Azathioprine’s myelosuppressive effects and infection risk have no offsetting mechanistic benefit in this condition.

Please also refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no supporting trials or literature (Evidence Level L5) and no plausible mechanistic link to azathioprine’s action. The high score from the TxGNN model (deep learning) may reflect similarities the model learned between related diseases, not biological evidence, and the safety profile offers no compensating benefit.

To proceed, the following is needed:

Any mechanistic or preclinical rationale connecting purine antimetabolite immunosuppression to this syndrome’s pathophysiology
Detailed mechanism of action data for azathioprine
Package insert warnings and contraindications for the India-marketed products
Consideration of TPMT/NUDT15 genotyping and blood count and liver monitoring as guardrails
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.